Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Oxybutynin Topical Gel in Overactive Bladder
NCT00350636Phase 3Completed
- Sponsor
- Watson Pharmaceuticals
- Start
- Jun 2006
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxybutynin in overactive bladder (OAB), sponsored by Watson Pharmaceuticals. Started Jun 2006; status: completed.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00350636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00350636.